Generic Name: Interferon beta-1a SubQ injection
Rebif, a brand name for interferon beta-1a, is an immunomodulator used to prevent episodes of symptoms and slow the development of disability in patients with relapsing-remitting multiple sclerosis. It is given subcutaneously (under the skin) three times a week, ideally the same 3 days each week.
| Reasons taken | # of patients | Major | Moderate | Slight | None | Can’t tell | # of patients evaluated by |
|---|---|---|---|---|---|---|---|
| Slow my MS progress | 841 |
|
|
|
|
|
158 |
| Multiple Sclerosis (MS) | 77 |
|
|
|
|
|
31 |
| Other | 28 |
|
|
|
4 | ||
| Stiffness/Spasticity | 8 |
|
|
2 | |||
| General health | 8 |
|
|
|
|
4 | |
| Don't know | 5 | 0 |
See all 794 patients currently taking Rebif
Mouse over the table for more information
Top 10 dosages based on patients currently taking Rebif. See all 81 dosages ►
| 22 mcg/0.5 mL as needed | 22mcg/0.5mL as needed | 3 times a week | 44 mcg/0.5 mL all the time (24/7) | 44 mcg/0.5 mL as needed | 44mcg/0.5mL as needed | 44mcg as needed | 44 mg all the time (24/7) | 44mg as needed | - as needed | as needed | daily | monthly | weekly | 0.14 mcg | 0.44 mg weekly | 0.5 mcg weekly | 0.44 mcg | 0.5 mcg | 0.44 mg | 0.8 mcg | 1 mcg | 3 mcg weekly | 3 mg weekly | 4.4 mcg weekly | 30 mcg/0.5 mL monthly | 8.8 mcg weekly | 3 mcg | 4.4 mcg | 15 mcg weekly | 22 mcg/0.5 mL weekly | 22 mcg weekly | 22 mg weekly | 26.4 mcg weekly | 10 mcg | 33 mg weekly | 12 mcg | 40 mcg weekly | 44 mcg/0.5 mL weekly | 44 mcg weekly | 44 mg weekly | 8.8 mcg daily | 8.8 mg daily | 22 mcg | 22 mcg/0.5 mL | 22 mcg/0.5 mL 3 times a week | 3 x 22 mcg/0.5 mL weekly | 66 mcg weekly | 66 mg weekly | 22 mcg | 2 x 44 mcg/0.5 mL weekly | 88 mcg weekly | 33 mcg | 99 mcg weekly | 112 mcg weekly | 40 mcg | 120 mg weekly | 12 x 44 mcg/0.5 mL monthly | 126 mcg weekly | 44 mcg | 44 mcg/0.5 mL 3 times a week | 132 mcg weekly | 132 mg weekly | 3 x 44 mcg/0.5 mL weekly | 152 mg weekly | 22 mcg/0.5 mL daily | 44 | 44 mcg | 44 mg | 4 x 44 mcg/0.5 mL weekly | 6 x 44 mcg/0.5 mL weekly | 100 mcg | 44 mcg/0.5 mL daily | 44 mcg/0.5 mL one time | 44 mcg daily | 132 mcg | 138 mcg | 132 mcg daily | 3 x 44 mcg/0.5 mL daily | 321 mcg | 44 mcg | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
1
|
2
|
31
|
1
|
3
|
8
|
2
|
1
|
1
|
1
|
4
|
12
|
1
|
23
|
1
|
1
|
1
|
2
|
1
|
1
|
1
|
1
|
2
|
3
|
1
|
1
|
1
|
1
|
1
|
1
|
6
|
2
|
3
|
1
|
1
|
1
|
1
|
1
|
54
|
27
|
15
|
1
|
1
|
8
|
1
|
15
|
28
|
3
|
2
|
2
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
87
|
55
|
29
|
16
|
150
|
1
|
12
|
4
|
17
|
21
|
1
|
1
|
1
|
75
|
1
|
10
|
1
|
1
|
1
|
2
|
1
|
1
|
||
| Reason | # Patients | Percentage of patients | |
|---|---|---|---|
|
Side effects too severe
|
167 | 48% |
|
|
Did not seem to work
|
115 | 33% |
|
|
Doctor's advice
|
80 | 23% |
|
|
Other
|
58 | 17% |
|
|
Personal research
|
16 | 5% |
|
|
Expense
|
14 | 4% |
|
|
Not indicated
|
9 | 3% |
|
|
Course of treatment ended
|
8 | 2% |
|
See more information, including instructions, precautions, side effects, and interactions.
Report created on November 21, 2009.